← Back to patent-cliff list
SPH-4336
Tier C — Watch / tradeSPH-4336
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：CDK6, CDK4
Indications (approved)：Breast cancer, 脂肪肉瘤, Solid tumour, Metastatic breast cancer
Regional status
US
Discontinued
2023-08-31
EU
-
China
Phase III
2023-04-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SPH-4336?
Approved indications include: Breast cancer, 脂肪肉瘤, Solid tumour, Metastatic breast cancer.
When does the SPH-4336 patent expire?
No public expiry year is available for SPH-4336 yet; this page updates once verified.
How do I get a quote for SPH-4336 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21